Medivation again jumps on Xtandi data

Medivation Inc. (NASDAQ:MDVN) added $8.72 (16%) to $62.61 on Wednesday following Tuesday's interim analysis of the Phase III PREVAIL trial that showed enzalutamide met the co-primary endpoints in chem...